Proeasome inhibition with bortezomib (PS-341) in combination with docetaxel (Doc) in prostate cancer (CaP) cells and xenografts.

被引：0
|
作者：
Farneth, NC [1 ]
Holland, WS [1 ]
Kenosi, T [1 ]
Kimura, T [1 ]
Lara, PN [1 ]
Gandara, DR [1 ]
Gumerlock, PH [1 ]
机构：
[1] Univ Calif Davis, Sacramento, CA 95817 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：239S / 239S
页数：1
相关论文
共 22 条
  • [1] Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy
    Lara, PN
    Davies, AM
    Mack, PC
    Mortenson, MM
    Bold, RJ
    Gumerlock, PH
    Gandara, DR
    SEMINARS IN ONCOLOGY, 2004, 31 (01) : 40 - 46
  • [2] Differential in vivo activity of docetaxel plus PS-341 combination therapy in non-small cell lung carcinoma (NSCLC) xenografts.
    Gumerlock, PH
    Kimura, T
    Holland, WS
    Shih, CDD
    Lara, PN
    Gandara, DR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 652S - 652S
  • [3] Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors
    Messersmith, WA
    Baker, SD
    Dinh, K
    Lassiter, LK
    Akdamar, RA
    Wright, JJ
    Donehower, RC
    Carducci, MA
    Armstrong, DK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 208S - 208S
  • [4] p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells
    Hideshima, T
    Podar, K
    Chauhan, D
    Ishitsuka, K
    Mitsiades, C
    Tai, YT
    Hamasaki, M
    Raje, N
    Hideshima, H
    Schreiner, G
    Nguyen, AN
    Navas, T
    Munshi, NC
    Richardson, PG
    Higgins, LS
    Anderson, KC
    ONCOGENE, 2004, 23 (54) : 8766 - 8776
  • [5] p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells
    Teru Hideshima
    Klaus Podar
    Dharminder Chauhan
    Kenji Ishitsuka
    Constantine Mitsiades
    Yu-Tzu Tai
    Makoto Hamasaki
    Noopur Raje
    Hiromasa Hideshima
    George Schreiner
    Aaron N Nguyen
    Tony Navas
    Nikhil C Munshi
    Paul G Richardson
    Linda S Higgins
    Kenneth C Anderson
    Oncogene, 2004, 23 : 8766 - 8776
  • [6] p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
    Hideshima, T
    Podar, K
    Chauhan, D
    Ishitsuka, K
    Mitsiades, C
    Tai, YT
    Hamasaki, M
    Raje, N
    Hideshima, H
    Schreiner, G
    Nguyen, A
    Navas, T
    Munshi, NC
    Richardson, PG
    Higgins, LS
    Anderson, KC
    BLOOD, 2004, 104 (11) : 915A - 915A
  • [7] Assessment of apoptosis-inducing effects of Docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells
    Jung, Cecilia S.
    Zhou, Zhongmei
    Khuri, Fadlo R.
    Sun, Shi-Yong
    CANCER BIOLOGY & THERAPY, 2007, 6 (05) : 749 - 754
  • [8] The combination of the proteasome inhibitor, PS-341, and docetaxel inhibits angiogenesis and overcomes cell-cycle mediated resistance in pancreatic cancer.
    Nawrocki, ST
    Sweeney-Gotsch, B
    Takamori, R
    McConkey, DJ
    TOXICOLOGICAL SCIENCES, 2003, 72 : 66 - 67
  • [9] Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezotnib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC)
    Lara, P.
    Longmate, J.
    Argiris, A.
    Gitlitz, B. J.
    Mack, P. C.
    Lau, D. H.
    Koczywas, M.
    Leighl, N. B.
    Gandara, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells
    Hideshima, Teru
    Podar, Klaus
    Chauhan, Dharminder
    Ishitsuka, Kenji
    Mitsiades, Constantine
    Tai, Yu-Tzu
    Hamasaki, Makoto
    Raje, Noopur
    Hideshima, Hiromasa
    Schreiner, George
    Nguyen, Aaron N.
    Navas, Tony
    Munshi, Nikhil C.
    Richardson, Paul G.
    Higgins, Linda S.
    Anderson, Kenneth C.
    ONCOGENE, 2024, 43 (40) : 3018 - 3018
123